Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19
Clinical narrative: COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included DVT (blood clots left left amd PE left side) in September 2020 and Knee replacement (Left knee) in October 2021. Concurrent medical conditions included Mitral valve prolapse, Penicillin allergy and Sulfonamide allergy. Concomitant products included FAMOTIDINE and MOMETASONE FUROATE for an unknown indication.   On 27-Mar-2021 at 9:00 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 06-Dec-2021 at 9:00 AM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-May-2022 at 9:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 23-May-2022 to May 2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) outcome was unknown.            Patient had reported nausea and vomiting occurred 6 hours after first dose. no re-occurrence after first dose on 24-May-2022. Day two of treatment adverse taste in month after every dose. my last dose will be Saturday morning 28-May-2022 Company comment: This spontaneous case concerns a 67-year-old, male patient with no relevant medical history, who experienced the unexpected, non-serious AESI of COVID-19. The exact date of onset of the event was not specified in respect to the administration of mRNA-1273, hence latency could not be assessed. The initial two doses of mRNA-1273 were given 7 months prior to the administration of third dose of mRNA-1273, the interval between the two doses is 35 days. It has been reported that nausea and vomiting occurred after 6 hours of first dose, and adverse taste was experienced after every dose. Patient was started with Paxlovid on May 23, 2022, to unknown outcome. Details of concomitant medications, clinical course, treatment and outcome were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 67-year-old, male patient with no relevant medical history, who experienced the unexpected, non-serious AESI of COVID-19. The exact date of onset of the event was not specified in respect to the administration of mRNA-1273, hence latency could not be assessed. The initial two doses of mRNA-1273 were given 7 months prior to the administration of third dose of mRNA-1273, the interval between the two doses is 35 days. It has been reported that nausea and vomiting occurred after 6 hours of first dose, and adverse taste was experienced after every dose. Patient was started with Paxlovid on May 23, 2022, to unknown outcome. Details of concomitant medications, clinical course, treatment and outcome were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.